Trial · NCT02942004
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score | Baseline, Hour 60 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Overall number of participants analyzed is the number of participants with data available for analysis at the given time-point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in HAM-D Total Score at Day 30 | Baseline, Day 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Overall number of participants analyzed is the number of participants with data available for analysis at the given time-point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in HAM-D Total Score | Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With HAM-D Response | Hour 60, Days 7 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With HAM-D Remission | Hour 60, Days 7 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in HAM-D Bech 6 Subscale | Baseline, Hour 60, Days 7 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in HAM-D Individual Item Scores | Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Baseline, Hour 60, Days 7 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response | Hour 60, Days 7 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score | Baseline, Hour 60, Days 7, 14, 21 and 30 | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With Treatment-Emergent Adverse Events | Up to approximately 37 days. | The Safety Set included all randomized participants who started the study drug infusion. | percentage of participants | NUMBER |
| SECONDARY | Time to Change in Antidepressant Medication | Up to approximately 37 days. | All randomized participants who started study drug infusion, had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Number analyzed is the number of participants with data available for analysis at the given time point. | days | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02942004/outcomes